Advertisement

Loading...

InnoCare Pharma Limited

9969.HKHKSE
Healthcare
Biotechnology
HK$15.49
HK$1.93(14.23%)
Hong Kong Market is Open • 11:48

InnoCare Pharma Limited (9969.HK) Stock Competitors & Peer Comparison

See (9969.HK) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
9969.HKHK$14.86+9.59%22.2B34.56HK$0.43N/A
6160.HKHK$185.00+7.81%277.9B124.16HK$1.49N/A
1801.HKHK$90.90+7.07%156.4B171.51HK$0.53N/A
2269.HKHK$34.86+5.57%144.1B26.61HK$1.31N/A
9926.HKHK$139.20+6.91%128.1B-127.71-HK$1.09N/A
1177.HKHK$6.36+7.98%113.8B42.40HK$0.15+1.53%
9995.HKHK$110.40+15.24%60.7B75.10HK$1.47N/A
1530.HKHK$25.32+11.84%59.7B23.23HK$1.09+1.10%
3759.HKHK$20.88+10.95%57B21.53HK$0.97+1.16%
2696.HKHK$75.90+8.82%41.3B44.39HK$1.71N/A
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

9969.HK vs 6160.HK Comparison April 2026

9969.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 9969.HK stands at 22.2B. In comparison, 6160.HK has a market cap of 277.9B. Regarding current trading prices, 9969.HK is priced at HK$14.86, while 6160.HK trades at HK$185.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

9969.HK currently has a P/E ratio of 34.56, whereas 6160.HK's P/E ratio is 124.16. In terms of profitability, 9969.HK's ROE is +0.09%, compared to 6160.HK's ROE of +0.07%. Regarding short-term risk, 9969.HK is more volatile compared to 6160.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 9969.HK.Check 6160.HK's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions